Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEONY: DE-117 vs Latanoprost in Glaucoma/OHT
NCT02981446Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jan 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of omidenepag isopropyl in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Mean Diurnal Intraocular Pressure at Month 3. Started Jan 2017; status: completed.
02
Drugs
omidenepag isopropyl
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT02981446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02981446.